Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23618692 | 0.84 | DGAT1 (0.48) | DGAT1IKBKBMAP2K2MAP2K1TDP1 | |
| SCHEMBL3530679 | 0.84 | KEAP1 (0.50) | TDP1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL1203088 | 0.83 | DGAT1 (0.45) | DGAT1IKBKBMAP2K2MAP2K1MAPT | |
| SCHEMBL31413282 | 0.83 | MAPK1 (0.46) | IKBKBTDP1SIRT3NNMTBRD4 | |
| SCHEMBL5951698 | 0.83 | MAPK1 (0.46) | IKBKBTDP1SIRT3NNMTBRD4 | |
| SCHEMBL17774979 | 0.81 | DGAT1 (0.44) | DGAT1IKBKBMAP2K2MAP2K1BRD4 | |
| SCHEMBL13885293 | 0.81 | NNMT (0.43) | IKBKBTDP1SIRT3NNMTBRD4 | |
| SCHEMBL23813891 | 0.79 | ALDH1A1 (0.41) | MAPTL3MBTL1KDM4ELMNAHTT | |
| SCHEMBL31473552 | 0.79 | GAA (0.46) | IKBKBMAP2K2MAP2K1HDAC1HDAC6 | |
| SCHEMBL376859 | 0.79 | KDM4E (0.56) | IKBKBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872822-B2 | Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition | L'OREAL (FR) | 2018-01-23 | — | — | US | disclosed |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | L'OREAL (FR) | 2016-05-26 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | DGAT1 4531/4885IKBKB 101/4885MAP2K2 178/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | DGAT1 4380/4885IKBKB 173/4885MAP2K2 262/4885 |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | KRT18, ARSA, SQOR | DGAT1 849/4885IKBKB 3089/4885MAP2K2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.